AAV and LVV Gene Therapy Research Insights
Cell and gene therapy research offers immense potential for advancing medicine, but it also involves significant challenges. This webinar dives into the experiences of experts working with adeno-associated viral (AAV) and lentiviral vector (LVV) based gene therapies.
Watch now to gain practical insights and learn best practices to enhance your advanced therapy research. Topics covered include sourcing materials appropriate for each phase, manufacturing strategies, regulatory considerations, and the importance of planning with the final product in mind. The presentation will also provide a brief overview of the gene therapy research products and services available through Charles River.
About the Presenters
James J. Cody
Associate Director, Technical Evaluations, Charles River
John Reece-Hoyes
Senior Director, Head of Vector Biology, Affinia Therapeutics
Matt Seefeldt
Executive Director, Gates Biomanufacturing Facility
Alison Halliday
Moderator, Writer, Freelance Science